Arthur F Kavanaugh

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study
    Mari Hoff
    Department of Rheumatology, St, Olavs Hospital, 7006 Trondheim, Norway
    BMC Musculoskelet Disord 12:54. 2011
  2. ncbi Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled
    Vibeke Strand
    Division of Immunology Rheumatology, Stanford University School of Medicine, 306 Ramona Road, Palo Alto, CA, 94028, USA
    Arthritis Res Ther 11:R170. 2009
  3. ncbi Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab
    Sanna Rosengren
    Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Arthritis Res Ther 10:R105. 2008
  4. ncbi The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
    Chenglong Han
    Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, Pennsylvania 19355, USA
    Arthritis Res Ther 9:R103. 2007
  5. ncbi Quality indicators in psoriatic arthritis
    A Kavanaugh
    University of California at San Diego, San Diego, CA, USA
    Clin Exp Rheumatol 25:98-101. 2007
  6. ncbi Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA, and University Hospital Leuven, Belgium
    Ann Rheum Dis 66:498-505. 2007
  7. ncbi Defining remission in psoriatic arthritis
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093 0943, USA
    Clin Exp Rheumatol 24:S-83-7. 2006
  8. ncbi Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis
    Arthur Kavanaugh
    Division of Rheumatology, Allergy and Immunology, University of California at San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA
    J Rheumatol 33:2254-9. 2006
  9. ncbi Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093, USA
    Nat Clin Pract Rheumatol 2:346-7. 2006
  10. ncbi Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis
    Arthur Kavanaugh
    The Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, California 92093 0943, USA
    Curr Opin Rheumatol 18:347-53. 2006

Detail Information

Publications87

  1. ncbi Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study
    Mari Hoff
    Department of Rheumatology, St, Olavs Hospital, 7006 Trondheim, Norway
    BMC Musculoskelet Disord 12:54. 2011
    ..The objective of this study was to examine if treatment with the TNF-? inhibitor adalimumab also could reduce periarticular bone loss in RA patients independent of disease activity...
  2. ncbi Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled
    Vibeke Strand
    Division of Immunology Rheumatology, Stanford University School of Medicine, 306 Ramona Road, Palo Alto, CA, 94028, USA
    Arthritis Res Ther 11:R170. 2009
    ..The objective of this study was to assess the impact of certolizumab pegol (CZP) treatment on health-related quality of life (HRQoL), fatigue and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA)...
  3. ncbi Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab
    Sanna Rosengren
    Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Arthritis Res Ther 10:R105. 2008
    ....
  4. ncbi The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
    Chenglong Han
    Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, Pennsylvania 19355, USA
    Arthritis Res Ther 9:R103. 2007
    ..Patients in large randomized controlled studies of infliximab in RA, PsA, and AS had similar impairment in physical aspects of HRQoL at baseline and showed significantly greater improvement in HRQoL after treatment with infliximab...
  5. ncbi Quality indicators in psoriatic arthritis
    A Kavanaugh
    University of California at San Diego, San Diego, CA, USA
    Clin Exp Rheumatol 25:98-101. 2007
    ..As such, these guidelines will form the basis for identifying what constitutes quality medical care for patients with PsA...
  6. ncbi Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA, and University Hospital Leuven, Belgium
    Ann Rheum Dis 66:498-505. 2007
    ..To evaluate the efficacy and safety of infliximab through 1 year in patients with psoriatic arthritis (PsA) enrolled in the IMPACT 2 trial...
  7. ncbi Defining remission in psoriatic arthritis
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093 0943, USA
    Clin Exp Rheumatol 24:S-83-7. 2006
    ..In this paper we present a number of key principles and considerations critical to laying the groundwork for defining remission in PsA...
  8. ncbi Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis
    Arthur Kavanaugh
    Division of Rheumatology, Allergy and Immunology, University of California at San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA
    J Rheumatol 33:2254-9. 2006
    ..To examine the effect of infliximab on employment status, time lost from work, and productivity in a double-blind, placebo-controlled study of patients with active psoriatic arthritis (PsA)...
  9. ncbi Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093, USA
    Nat Clin Pract Rheumatol 2:346-7. 2006
  10. ncbi Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis
    Arthur Kavanaugh
    The Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, California 92093 0943, USA
    Curr Opin Rheumatol 18:347-53. 2006
    ..The greatest experience has accrued in ankylosing spondylitis and psoriatic arthritis. This paper reviews data from clinical trials with tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis...
  11. ncbi B cell targeted therapies: safety considerations
    Arthur F Kavanaugh
    Center for Innovative Therapy, University of California San Diego, San Diego, California 92093 0943, USA
    J Rheumatol Suppl 77:18-23. 2006
    ....
  12. ncbi The pharmacoeconomics of newer therapeutics for rheumatic diseases
    Arthur Kavanaugh
    Division of Rheumatology, Allergy, and Immunology, University of California at San Diego, La Jolla, CA 92093 0943, USA
    Rheum Dis Clin North Am 32:45-56, viii. 2006
    ..This issue has been analyzed in greatest detail in rheumatoid arthritis. Increasing data suggest that newer therapeutics may be cost-effective for rheumatoid arthritis and other rheumatic diseases...
  13. ncbi Economic issues with new rheumatologic therapeutics
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093 0943, USA
    Curr Opin Rheumatol 19:272-6. 2007
    ..Brought to the clinic initially for the treatment of rheumatoid arthritis, biologic agents have found expanded indication in other rheumatic diseases...
  14. ncbi Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results
    A Kavanaugh
    University of California, San Diego, Division of Rheumatology, Allergy, and Immunology, 9500 Gilman Drive, Mail Code 0943, La Jolla, CA 92093 0943, USA
    Ann Rheum Dis 67:402-8. 2008
    ..Marked depletion of circulating B cells, seen in almost all patients, does not correlate with efficacy. The potential synovial immunomodulatory effects of rituximab have not been fully defined...
  15. ncbi Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, The University of California at San Diego, La Jolla, California 92093 0943, USA
    Bull NYU Hosp Jt Dis 65:S16-20. 2007
    ..Data from studies currently underway will help refine the ultimate use of this novel approach to treatment, and help clinicians optimize therapy using this approach...
  16. ncbi Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial
    Arthur Kavanaugh
    Division of Rheumatology, Allergy, and Immunology, San Diego, CA, USA
    Curr Med Res Opin 26:2385-92. 2010
    ....
  17. ncbi Patient-derived joint counts are a potential alternative for determining Disease Activity Score
    Arthur Kavanaugh
    Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA 92037 0943, USA
    J Rheumatol 37:1035-41. 2010
    ..To investigate the correlation between the Disease Activity Score using a 28-joint count (DAS28) based on physician-derived joint counts and the DAS28 based on patient-derived joint counts (Pt-DAS28) in rheumatoid arthritis (RA)...
  18. ncbi Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis
    Arthur Kavanaugh
    Center for Innovative Therapy, University of California, San Diego, Division of Rheumatology, Allergy and Immunology, 9500 Gilman Drive, Mail Code 0943, La Jolla, CA 92093 0943, USA
    Arthritis Rheum 61:1592-600. 2009
    ....
  19. ncbi Therapy: Guidelines in rheumatology: quo vadis?
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093 0943, USA
    Nat Rev Rheumatol 5:423-4. 2009
    ..The implementation of evidence-based guidelines designed to inform clinicians' decisions requires careful consideration of several important issues...
  20. ncbi Infection prophylaxis in antirheumatic therapy: emphasis on vaccination
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California 92093 0943, USA
    Curr Opin Rheumatol 21:419-24. 2009
    ..To assess data concerning vaccination among persons with rheumatic diseases, focusing on the effects of immune-modulating therapeutic agents on the responses...
  21. ncbi Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study
    Arthur Kavanaugh
    University of California, San Diego, La Jolla, CA 92093 0943, USA
    Arthritis Rheum 60:976-86. 2009
    ..To assess the efficacy and safety of golimumab in patients with active psoriatic arthritis (PsA)...
  22. ncbi Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, UCSD, San Diego, California, USA
    Ann Rheum Dis 67:1444-7. 2008
    ..Whereas many patients respond quickly to treatment with tumour necrosis factor (TNF) inhibitors, some patients may experience significant but delayed responses...
  23. ncbi Economic consequences of established rheumatoid arthritis and its treatment
    Arthur Kavanaugh
    Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA 92093 0943, USA
    Best Pract Res Clin Rheumatol 21:929-42. 2007
    ..Therefore, it is appropriate for pharmacoceconomic analyses to take into account all relevant costs, not only of the treatments, but of the disease itself. In this way, the value of therapies can be correctly estimated...
  24. ncbi The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year
    A Kavanaugh
    Center for Innovative Therapy, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Ann Rheum Dis 65:1038-43. 2006
    ..Using IMPACT trial data, we assessed the effect of infliximab (IFX) on structural damage in PsA...
  25. ncbi The assessment of disease activity and outcomes in psoriatic arthritis
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Clin Exp Rheumatol 23:S142-7. 2005
    ..To date, such measures have largely been adapted from related diseases, as described in this essay. Further research is needed to further develop outcome measures for PsA to facilitate optimal treatment of patients with PsA...
  26. ncbi Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California at San Diego, La Jolla, California 92093, USA
    J Rheumatol 31:849-55. 2004
    ..We also assessed the influence of improvement in physical function on employability, healthcare costs, and quality of life, utilizing data collected in the ATTRACT trial...
  27. ncbi Ethical and practical issues in conducting clinical trials in psoriasis and psoriatic arthritis
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, CA 92093 0943, USA
    Ann Rheum Dis 64:ii46-8. 2005
    ..Because of these developments, there is a need to continually assess the design of current and future research studies so that they may be conducted in the optimal and most ethical manner...
  28. ncbi Outcome measures in psoriatic arthritis
    Arthur Kavanaugh
    Division of Rheumatology, Allergy, and Immunology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Curr Rheumatol Rep 7:195-200. 2005
    ..To date, such measures have largely been adapted from other similar diseases. With further research, the most appropriate outcome measures specific for PsA will be delineated...
  29. ncbi Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis
    A Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Ann Rheum Dis 65:471-7. 2006
    ..To evaluate the effect of infliximab on health related quality of life (HRQoL) and physical function in patients with active psoriatic arthritis (PsA) in the IMPACT 2 trial...
  30. ncbi Health economics: implications for novel antirheumatic therapies
    A Kavanaugh
    Center for Innovative Therapy and Division of Rheumatology, Allergy, and Immunology, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Ann Rheum Dis 64:iv65-9. 2005
    ....
  31. ncbi Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial
    Arthur Kavanaugh
    Division of Rheumatology, Allergy and Immunology, University of California, San Diego, San Diego, CA 92037 0943, USA
    J Rheumatol 30:449-54. 2003
    ..AG4263 is a soluble complex of native HLA-DR4 (beta*0401) complexed to Org 36601, a 13-mer peptide derived from HC gp-39 (also referred to as CDP263)...
  32. ncbi Combination cytokine therapy: the next generation of rheumatoid arthritis therapy?
    Arthur Kavanaugh
    The University of California, San Diego, USA
    Arthritis Rheum 47:87-92. 2002
  33. ncbi Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests
    Arthur F Kavanaugh
    Division of Rheumatology, Allergy, and Immunology, University of California at San Diego, San Diego, CA 92037, USA
    Arthritis Rheum 47:546-55. 2002
  34. ncbi Minimally important differences of the gout impact scale in a randomized controlled trial
    Dinesh Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, University of California at San Diego, La Jolla, CA 90095, USA
    Rheumatology (Oxford) 50:1331-6. 2011
    ..Our objective was to assess minimally important differences (MIDs) for the GIS administered in a randomized controlled trial (RCT) assessing rilonacept vs placebo for prevention of gout flares during initiation of allopurinol therapy...
  35. ncbi Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis
    Jeremy Sokolove
    Stanford University, Palo Alto, CA, USA
    Ann Rheum Dis 69:1612-7. 2010
    ....
  36. ncbi Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment
    Andrew J Sarkin
    Health Services Research Center, University of California, San Diego, California, USA
    J Eval Clin Pract 16:1244-7. 2010
    ....
  37. ncbi Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008
    Christopher T Ritchlin
    Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA
    J Rheumatol 37:462-7. 2010
    ..The appearance of new therapeutic options in PsA raises the need for sensitive biomarkers for both disease activity and outcome...
  38. ncbi Therapies for psoriatic nail disease. A systematic review
    Sarah Cassell
    Division of Rheumatology, Allergy, and Immunology, University of California at San Diego, La Jolla, California 92093-0943, USA
    J Rheumatol 33:1452-6. 2006
    ..The lack of standardized outcome assessments hinders the interpretation of available data. In this systematic evidence-based review of the literature, we assess various treatments for psoriatic nail disease...
  39. ncbi Secondary immune deficiencies associated with biological therapeutics
    Susan J Lee
    Division of Rheumatology, Allergy and Immunology, Center for Innovative Therapy, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0943, USA
    Curr Allergy Asthma Rep 3:389-95. 2003
    ..Both clinical and in vitro studies have been done to explore the potential immunomodulatory and immunosuppressive effects of these agents...
  40. ncbi Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies
    Hal M Hoffman
    Division of Rheumatology and Allergy Immunology, University of California at San Diego, La Jolla, CA 92093 0635, USA
    Arthritis Rheum 58:2443-52. 2008
    ....
  41. ncbi Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
    Robin K Dore
    Robin K Dore Inc, Tustin, CA, USA
    Ann Rheum Dis 69:872-5. 2010
    ....
  42. ncbi Quantitative biomarker analysis of synovial gene expression by real-time PCR
    David L Boyle
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, California, USA
    Arthritis Res Ther 5:R352-60. 2003
    ..The technique can potentially be used in serial biopsy studies to provide insights into mechanism of action and therapeutic effect of new anti-inflammatory agents...
  43. ncbi Tumor necrosis factor as a therapeutic target of rheumatologic disease
    Christoph Ackermann
    University of California, Center for Innovative Therapy, Divison of Rheumatology, Allergy and Immunology, San Diego, La Jolla, CA 92093 0943, USA
    Expert Opin Ther Targets 11:1369-84. 2007
    ..In addition to the presently available TNF-alpha blockers, other agents targeting this key mediator are under study. Recent advances and future directions in anti-TNF-alpha therapy are discussed in this paper...
  44. ncbi Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study
    Susan J Lee
    Veterans Affairs San Diego Healthcare System, and University of California, San Diego, Department of Medicine, San Diego, California, USA
    J Rheumatol 36:1611-7. 2009
    ..To determine whether these findings have altered practice patterns, we used the Consortium of Rheumatology Researchers of North America (CORRONA) registry to assess the pattern of TNF inhibitor utilization in the US over time...
  45. ncbi Perceptions of disease and health-related quality of life among patients with gout
    Susan J Lee
    San Diego Veterans Affairs Medical Center, San Diego, CA, USA
    Rheumatology (Oxford) 48:582-6. 2009
    ..To assess the impact of gout on health-related quality of life (HRQoL) among patients in three large US cities...
  46. ncbi Biologic therapy for early rheumatoid arthritis: the latest evidence
    Hernan Castro-Rueda
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, California, USA
    Curr Opin Rheumatol 20:314-9. 2008
    ..To describe current therapeutic trials with biologic agents for early rheumatoid arthritis, analyzing clinical and radiographic outcomes...
  47. ncbi Evaluation of an instrument assessing influence of Gout on health-related quality of life
    Jan D Hirsch
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093 0714, USA
    J Rheumatol 35:2406-14. 2008
    ..To evaluate the reliability and validity of an instrument assessing the influence of gout (acute and chronic) on health-related quality of life (HRQOL)...
  48. ncbi The pathobiology of psoriatic synovium
    David L Boyle
    Rheumatology, Allergy, Immunology Division, University of California, San Diego, California 92093, USA
    Curr Opin Rheumatol 20:404-7. 2008
    ..Currently, approaches similar to those applied to rheumatoid arthritis are being applied to psoriatic arthritis synovia...
  49. ncbi Electronic and computer-generated patient questionnaires in standard care
    Susan J Lee
    Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, 9320 Campus Point Dr Suite 225, Mailcode 0943, La Jolla, CA 92037 0943, USA
    Best Pract Res Clin Rheumatol 21:637-47. 2007
    ....
  50. ncbi Rheumatic disease in the elderly: rheumatoid arthritis
    Zuhre Tutuncu
    Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, CA 92093 0943, USA
    Clin Geriatr Med 21:513-25, vi. 2005
    ..There is definitely a substantial need for improving different aspects of diagnostic and therapeutic interventions that will reduce the impact of inflammatory arthritis in the growing elderly population...
  51. ncbi Recent developments in diet and gout
    Susan J Lee
    Center for Innovative Therapy, University of San Diego, La Jolla, California 92037, USA
    Curr Opin Rheumatol 18:193-8. 2006
    ..This review focuses on recent developments and their implications for clinical practice, including how we advise patients on appropriate diets and alcoholic beverage consumption...
  52. ncbi Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents
    Zuhre Tutuncu
    Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla 92093 0943, USA
    Arthritis Rheum 52:2693-6. 2005
    ....
  53. ncbi Rheumatoid arthritis in dermatology
    Tissa Hata
    Department of Medicine, Division of Dermatology, University of California, San Diego School of Medicine, La Jolla, 92093 0943, USA
    Clin Dermatol 24:430-7. 2006
    ..Understanding the etiology and therapy for cutaneous manifestations of RA will help optimize patient care...
  54. ncbi Biologic agents in rheumatology: safety considerations
    Susan J Lee
    Division of Rheumatology, Allergy, and Immunology, The University of California, San Diego, USA
    Rheum Dis Clin North Am 32:3-10. 2006
  55. ncbi Rheumatic disease in the elderly: rheumatoid arthritis
    Zuhre Tutuncu
    Division of Rheumatology, Allergy and Immunology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0943, USA
    Rheum Dis Clin North Am 33:57-70. 2007
    ..There is substantial need for improving aspects of diagnostic and therapeutic interventions that will reduce the impact of inflammatory arthritis in the growing elderly population...
  56. ncbi An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis
    Michael E Weinblatt
    Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 363:1303-12. 2010
    ..The objective of this phase 2 study was to evaluate the efficacy and safety of R788, an oral inhibitor of Syk, in patients with active rheumatoid arthritis despite methotrexate therapy...
  57. ncbi CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis
    Sanna Rosengren
    Division of Rheumatology, Department of Medicine, Allergy and Immunology, University of California at San Diego School of Medicine, 9500 Gilman Drive, Mail Code 0656, La Jolla, CA 92093 0656, USA
    Rheumatology (Oxford) 50:603-10. 2011
    ..The B-cell chemokine, CXCL13, is a proposed serum biomarker of synovitis in RA. Its behaviour in the context of B-cell depletion therapy and reconstitution was studied during treatment of RA with rituximab...
  58. ncbi Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines
    Arthur F Kavanaugh
    University of California at San Diego, San Diego, California, USA
    J Rheumatol 33:1417-21. 2006
    ..We outline the specific methods and procedures used in this evidence-based, systematic review of treatments for PsA, which we hope will provide a basis for future treatment guidelines...
  59. ncbi Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins
    Susan J Lee
    Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, CA 92093 0943, USA
    J Allergy Clin Immunol 125:S314-23. 2010
    ..These agents have the potential both to optimize outcomes through more thorough modulation of specific parts of the dysregulated immune response and to minimize toxicity compared with less specific methods of immunosuppression...
  60. ncbi Pharmacological treatment of established rheumatoid arthritis
    Susan Jung-Ah Lee
    Division of Allergy, Immunology and Rheumatology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0943, USA
    Best Pract Res Clin Rheumatol 17:811-29. 2003
    ..The indications, efficacy and safety of these agents in clinical trials and practice are reviewed in this chapter...
  61. ncbi Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II tria
    Eva C Koffeman
    University of California, San Diego, La Jolla, CA, USA
    Arthritis Rheum 60:3207-16. 2009
    ....
  62. ncbi Factors affecting rheumatoid arthritis patients' decisions to participate in clinical trials
    Susan J Lee
    Division of Rheumatology, Allergy, Immunology, University of California, San Diego, California 92037-0943, USA
    J Rheumatol 32:2317-25. 2005
    ..Consideration of these factors may facilitate the inclusion of more diverse patient populations into trials and enhance the applicability of trial results...
  63. ncbi Current treatments for rheumatoid arthritis
    Arthur Kavanaugh
    University of California, San Diego, USA
    Am J Orthop 36:4-7. 2007
  64. ncbi Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial
    Maria Dall'Era
    Division of Rheumatology, University of California San Francisco 533 Parnassus Avenue, San Francisco, CA 94143, USA
    Arthritis Rheum 56:4142-50. 2007
    ..Atacicept is a TACI-Ig fusion protein that inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand...
  65. ncbi Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments
    Jeffry Bieber
    Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California at San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92037-0943, USA
    Rheum Dis Clin North Am 30:257-70, v. 2004
    ..Screening for latent TB infection with purified protein derivative is indicated for patients who are being considered for treatment; it seems to be effective in reducing the occurrence of TB in treated patients...
  66. ncbi Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis
    Arthur Kavanaugh
    Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, California 92093-0943, USA
    Adv Ther 23:208-17. 2006
    ..The biologic agent, anakinra, provides to patients with RA a valuable treatment option that has a positive impact on both function and quality of life...
  67. ncbi Treatment of psoriatic arthritis with biological agents
    Arnold Ceponis
    Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, CA 92037 0943, USA
    Semin Cutan Med Surg 29:56-62. 2010
    ..Herein we review the evidence regarding the treatment of PsA arthritis with biological agents...
  68. ncbi Adverse reactions to biologic agents: focus on autoimmune disease therapies
    Susan J Lee
    Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, CA 92093-0943, USA
    J Allergy Clin Immunol 116:900-5. 2005
    ..An understanding of the spectrum and types of reactions possible with biologic agents, as well as the mechanisms underlying such reactions, will help clinicians use them optimally...
  69. ncbi Economic burden of psoriatic arthritis
    Christoph Ackermann
    The Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, California 92093 0943, USA
    Pharmacoeconomics 26:121-9. 2008
    ..The notable clinical efficacy of the TNFalpha inhibitors needs to be factored into a comprehensive assessment of their value. Further analyses are needed to optimize the use of the new biologic agents in PsA...
  70. ncbi Biologic therapies for the treatment of asthma
    Amy L Wagelie-Steffen
    Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0637, USA
    Clin Chest Med 27:133-47, vii. 2006
    ..This article describes several potential novel biologic therapies that have been or could be investigated...
  71. ncbi The clinical efficacy of tocilizumab in rheumatoid arthritis
    Maja Mircic
    The Center for Innovative Therapy, Division of Rheumatology, Allergy, Immunology, The University of California, San Diego, La Jolla, California 92093 0943, USA
    Drugs Today (Barc) 45:189-97. 2009
    ..The largest amount of data to date comes from trials of the humanized anti-IL-6 receptor antibody tocilizumab. Studies worldwide have demonstrated the clinical efficacy of this agent in patients with RA...
  72. ncbi A web-compatible instrument for measuring self-reported disease activity in arthritis
    Ninad Athale
    Health Services Research and Development, Veterans Affairs San Diego Healthcare System, Veterans Medical Research Foundation, University of California, San Diego (UCSD, California 92161, USA
    J Rheumatol 31:223-8. 2004
    ....
  73. ncbi 4. Autoimmunity, vasculitis, and autoantibodies
    Susan J Lee
    Division of Rheumatology, Allergy, and Immunology, and the Center for Innovative Therapy, the University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    J Allergy Clin Immunol 117:S445-50. 2006
    ....
  74. ncbi The treatment of psoriatic arthritis and inflammatory spondylitis
    Hernan Castro-Rueda
    Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA 92093 0943, USA
    Curr Pain Headache Rep 12:412-7. 2008
    ..Factors such as cost-effectiveness and safety will need to be better characterized over time...
  75. ncbi Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial
    Dinesh Khanna
    David Geffen School of Medicine, and School of Public Health, University of California, Los Angeles, USA
    Arthritis Rheum 60:1102-11. 2009
    ....
  76. ncbi The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis
    Sarah E Cassell
    Division of Rheumatology, Allergy and Immunology, University of California, San Diego, San Diego, California, USA
    J Rheumatol 34:123-9. 2007
    ..Beginning with NAPSI, our goal was to validate a psoriatic nail assessment tool for use in clinical trials, and investigate correlations between nail and other PsA features...
  77. ncbi A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, USA
    J Rheumatol 32:2345-50. 2005
    ..We evaluated the safety and possible biologic effect of intradermal injections of PVAC in patients with diffuse SSc...
  78. ncbi Reading and interpreting economic evaluations in rheumatoid arthritis: an assessment of selected instruments for critical appraisal
    Michael H Weisman
    Evidence-Based Medicine Working Groups in Rheumatology, Beverly Hills, CA, USA
    J Rheumatol 30:1739-47. 2003
    ..Although consistency between reviewers was good on both guidelines, inter-guideline discrepancies were noted and reviewers reported some difficulty in using the operationalized format...
  79. ncbi Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled
    Edward C Keystone
    University of Toronto, Toronto, Ontario M5G 1X5, Canada
    Arthritis Rheum 50:1400-11. 2004
    ....
  80. ncbi The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo
    Ferdinand C Breedveld
    Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, C4 R Postbox 9600, Leiden 2300 RC, The Netherlands
    Arthritis Rheum 54:26-37. 2006
    ..To compare the efficacy and safety of adalimumab plus methotrexate (MTX) versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive rheumatoid arthritis (RA) who had not previously received MTX treatment...
  81. ncbi Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: comment on the article by Smolen et al
    Theodore Pincus
    Arthritis Rheum 52:4044-5; author reply 4045-7. 2005
  82. ncbi Macromolecule tumor necrosis factor inhibitors: are more better?
    Arthur F Kavanaugh
    J Rheumatol 32:2285-7. 2005
  83. ncbi Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus
    Michelle A Petri
    Johns Hopkins University Medical Center, Baltimore, Maryland 21205, USA
    Arthritis Rheum 50:2858-68. 2004
    ..To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SLE) disease activity and its symptoms...
  84. ncbi American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
    Kenneth G Saag
    University of Alabama, Birmingham, AL, USA
    Arthritis Rheum 59:762-84. 2008
  85. ncbi Evidence-based use of rheumatologic laboratory tests
    Arthur F Kavanaugh
    Arch Intern Med 164:109. 2004
  86. ncbi Outcome measures in psoriatic arthritis
    Dafna D Gladman
    University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto, Canada
    J Rheumatol 32:2262-9. 2005
    ..A set of domains to be included in the assessment of patients with PsA was derived, and a research agenda was developed...
  87. ncbi Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology
    Allan S Wiik
    Statens Serum Institut, Copenhagen, Denmark
    Arthritis Rheum 51:291-8. 2004